CLINICAL ANDVACCINEIMMUNOLOGY, Dec. 2006, p. 1363–1366 Vol. 13, No. 12
1556-6811/06/$08.00⫹0 doi:10.1128/CVI.00239-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Diagnosis of Paracoccidioidomycosis by Detection of Antigen and
Antibody in Bronchoalveolar Lavage Fluids
䌤
Silvia Helena Marques-da-Silva,
1Arnaldo Lopes Colombo,
2Maria Heloisa Souza Lima Blotta,
3Fla´vio Queiroz-Telles,
4Alı´pio Barbosa Balthazar,
5Jose´ Daniel Lopes,
1and Zoilo Pires de Camargo
1*
Department of Microbiology, Immunology, and Parasitology, Federal University of Sa˜o Paulo (UNIFESP), Sa˜o Paulo, Brazil1;
Division of Infectious Diseases, Federal University of Sa˜o Paulo (UNIFESP), Sa˜o Paulo, Brazil2; Department of
Clinical Pathology3and Department of Internal Medicine,5School of Medicine, State University of
Campinas (UNICAMP), Campinas, Sa˜o Paulo, Brazil; and Department of Community Health, School of Medicine, Federal University of Parana´, Curitiba, Parana´, Brazil4
Received 29 June 2006/Returned for modification 22 August 2006/Accepted 2 October 2006
Paracoccidioidomycosis (PCM) is a systemic infection caused by the fungusParacoccidioides brasiliensisand
is believed to be the leading cause of fungal pulmonary infection. In this study, we used an inhibition enzyme-linked immunosorbent assay to diagnose pulmonary PCM based on the detection of 43-kDa and 70-kDa molecules in bronchoalveolar lavage fluids. The results were compared with results obtained by classical methods for antibody detection.
Paracoccidioidomycosis (PCM) is a systemic endemic myco-sis caused by the dimorphic fungusParacoccidioides brasiliensis
that affects rural workers in Latin American countries (1, 6, 9). It has a wide spectrum of clinical manifestations, ranging from mild pulmonary lesions to severe disseminated forms involving many organs, especially the mucosae, skin, lymph nodes, adre-nals, and central nervous system (6, 9). The primary pulmonary infection is unapparent or oligosymptomatic in most cases, and individuals may remain infected throughout their lives without ever developing PCM. In most cases, symptomatic patients develop the disease years after acquiring the infection as a result of reactivation of the quiescent foci (chronic form) (3, 9, 10). Clinical findings in these patients generally include severe pulmonary involvement, followed by extrapulmonary dissemi-nation. In PCM, lung destruction involves the alveoli, intersti-tium, and bronchial tree, resulting in fibrosis, ventilatory dys-function, and hypoxemia (22). Tobo´n et al. (23) recently reported that late diagnosis and disseminated lung involve-ment are two conditions associated with a higher rate of pul-monary sequelae.
Definitive diagnosis of pulmonary PCM is based on the visualization of fungal elements characteristic ofP. brasiliensis
in biopsy material, respiratory secretion, or sputum culture. However, processing respiratory secretion for direct examina-tion is time-consuming. Culture is difficult because sputum is contaminated with bacteria and other yeasts such asCandida
sp. that inhibit the growth ofP. brasiliensis, a fastidious organ-ism, and bronchoscopy and lung biopsy may be difficult to perform in patients with severe respiratory dysfunction. Hence, serological methods based on antibody or antigen detection may be useful tools for diagnosis of the disease.
Marques-da-Silva et al. (15–18) recently described an antigen detection assay (the inhibition enzyme-linked immunosorbent assay [inh-ELISA]) for the gp43 and gp70 molecules ofP. brasiliensiswith good potential for use in diagnosis and follow-up of patients with PCM. The detection of P. brasiliensis antigens in body fluids might facilitate early diagnosis of PCM even in patients with pulmonary involvement.
In the present study, gp43 and gp70 antigens ofP. brasiliensis
were detected in bronchoalveolar lavage (BAL) fluid sam-ples from patients with pulmonary PCM using an inh-ELISA. The results were compared with those obtained for anti-P. brasiliensis antibodies detected by immunodiffusion (ID) tests and ELISA.
BAL fluid and serum samples were obtained from 27 pa-tients with pulmonary PCM. Papa-tients were selected based on clinical, serological, and chest roentgenogram findings as well as on direct examination of sputum, in which characteristicP. brasiliensismultibudding yeast cells were seen in all patients. The patients enrolled in this study were from Hospital Sa˜o Paulo, Sa˜o Paulo Federal University (UNIFESP), and Hospi-tal das Clı´nicas, State University of Campinas (UNICAMP), Campinas, Sa˜o Paulo, Brazil. All patients were male, with an average age of 46 years. They were subjected to bronchoalveo-lar lavage procedures. None were suffering from AIDS or other profoundly immunosuppressive conditions. Each lavage was performed with five 20-ml aliquots of preservative-free normal saline, and lavage fluids were then centrifuged at 2,500⫻gfor 10 min in a tabletop centrifuge to prepare sedi-ments for direct examination and cultures. The supernatants were stored at 4°C and heated to 56°C for 30 min before being tested for antigens. The cellular sediment was separated for direct examination with 30% KOH (characteristicP. brasilien-sismultibudding yeast cells were visualized in all sediments) and for culture, but no growth was obtained. In addition, se-rum samples from patients were tested for anti-P. brasiliensis
antibodies (immunodiffusion and ELISA) and for specificP. brasiliensisantigens (inh-ELISA). Control groups included 10 * Corresponding author. Mailing address: Universidade Federal de
Sa˜o Paulo (UNIFESP), Disciplina de Biologia Celular, 04023-062, Rua Botucatu, 862, 8° andar, Sa˜o Paulo, SP, Brazil. Phone: 55 11 5576 4523. Fax: 55 11 5571 5877. E-mail: zoilo@ecb.epm.br.
䌤Published ahead of print on 11 October 2006.
BAL fluid samples from patients with noninfectious diseases and 10 from patients with other infectious diseases such as tuberculosis. The study was evaluated and approved by the Ethics Committee of the Federal University of Sa˜o Paulo.
P. brasiliensisB-339 (ATCC 200273) was obtained from the culture collection of the Cell Biology Discipline, Federal Uni-versity of Sa˜o Paulo, and transformed to the yeast phase; exoan-tigen was produced according to the method of de Camargo et al. (4, 5), and gp43 and gp70 antigens were purified from this exoantigen (20, 21). Protein content was determined by the Bradford method (2). Anti-gp43 and anti-gp70 monoclonal antibodies (MAbs) were supplied by R. Puccia (21) and D. Mattos Grosso (20), respectively.
inh-ELISA was performed as previously described (11, 15). Aliquots of BAL fluid and serum samples (200l) were mixed with an equal volume of 0.1 M EDTA (Sigma), pH 7.2, and boiled at 100°C for 5 min. After cooling, tubes were centri-fuged at 13,000⫻gfor 30 min, and the supernatants were used for the test. First, a standard inhibition curve was prepared by adding known concentrations of gp43 or gp70 to a pool of normal human sera or BAL fluid controls in different plates (inhibition standards) (11, 15). The inhibition reaction oc-curred when constant aliquots of anti-gp43 or anti-gp70 MAbs were mixed with the inhibition standards, PCM patients’ sera or BAL fluid samples, and normal human sera and BAL fluid control samples. Samples were then plated on a previously blocked microtiter plate (inhibition plate) and incubated over-night at 4°C. The reaction plate was coated with gp43 or gp70 and incubated overnight at 4°C. Free sites on the polystyrene were blocked with 5% skim milk in phosphate-buffered saline (PBS)–Tween 20, and samples from each well in the inhibition plate (containing a mixture of MAb [anti-gp43 or anti-gp70] bound to circulating antigen and free MAb) were transferred to the respective wells in the reaction plate. The plate was washed, probed with goat anti-mouse immunoglobulin–peroxi-dase conjugate, and developed with a chromogenic substrate as previously described (11, 15). Optical density (OD) readings at 492 nm were then plotted on a standard curve constructed from the data derived from MAb titration with the inhibition standards. The antigen concentrations in the patients’ BAL fluid and serum samples were calculated with a regression model constructed with the reciprocal values of fixed concen-trations of gp43 or gp70 and the OD values. All tests were performed in duplicate. All specimens included here had been tested previously when they were first obtained and were tested again using the same technique in this study. Inhibition stan-dard curves were performed in duplicate for at least four in-dependent assays. Data were statistically analyzed using the Stata 7.0 program for Windows 98/95/NT (Stata Corporation, College Station, TX), and specificity and sensitivity were ana-lyzed using the receiver operator characteristic (ROC) curve. The sensitivity of the test ranged from 0.001 to 30g/ml.
ID tests were performed with BAL fluid samples and serum samples at the time of diagnosis as previously described (4). For the ELISAs, microtiter plates (Costar) were coated with 100l of purified gp43 or gp70 (500 ng/well), diluted in 0.06 M carbonate-bicarbonate buffer, pH 9.6, and incubated for 2 h at 37°C and overnight at 4°C. The plates were washed three times with PBS-Tween 20 (0.05%), and free sites were blocked with 5% skim milk in PBS-Tween (200 l/well) for 2 h at 37°C.
After three washes, 100 l of BAL fluid samples (1:50 to 1:51,200 dilution) from each patient was added to each well, and the plates were incubated at 37°C for 1 h. Plates were then washed again, 100l of peroxidase-labeled goat anti-human immunoglobulin (1:1,000 dilution; Sigma) was added to each well, and the plates were incubated for 1 h at 37°C. After 3 washes, the reaction was developed by adding 100 l of a mixture of O-phenylenediamine (0.2 mg/ml; Sigma) and 0.05% (vol/vol) H2O2in 0.1 M citrate buffer, pH 4.5. After
8 min of incubation in the dark, the reaction was stopped with 50l of 4 N H2SO4. OD was measured at 492 nm using
an ELISA microplate reader (Titertek Multiskan MCC/340). gp43 and gp70 antigens in BAL fluid were detected by pre-paring a standard inhibition curve and determining the cutoff values (0.23g/ml for gp43 and 0.21g/ml for gp70) using an ROC curve. BAL samples with concentrations above these values were considered positive. gp43 and gp70 were detected in all BAL fluid samples (100%). The mean antigen concen-tration found for gp43 (9.38g/ml) was significantly higher than that for gp70 (4.37g/ml,P⫽0.0001). BAL fluid samples from individuals with diseases other than PCM gave negative results (Table 1).
gp43 and gp70 were detected in sera by preparing a standard inhibition curve and determining the cutoff values (0.23g/ml for gp43 and 0.21g/ml for gp70) using an ROC curve. Sam-ples with concentrations above these values were considered positive. gp43 (mean, 15.53g/ml) and gp70 (mean, 7.86g/ ml) antigens were detected in all of the patients’ sera (P ⫽ 0.0001).
None of the 27 BAL fluid samples were positive for P. brasiliensiscrude exoantigen in immunodiffusion tests. How-ever, ID tests showed that 85.18% of the sera were positive, with antibody titers ranging from 1:8 to 1:64. When tested by ELISA, all BAL fluid samples (100%) had anti-gp43 and anti-gp70 antibodies, with titers ranging from 1:50 to 1:400 (Table 1).
Detection of circulating antigen is a useful approach for serodiagnosis in some invasive fungal diseases (7, 8, 14, 19) and may also be an alternative tool for diagnosing PCM patients. Gome´z et al. (11, 12) were the first researchers to use mono-clonal antibodies to detect an 87-kDa circulating antigen in PCM and achieved a sensitivity of 80.4%. Marques-da-Silva et al. (15–18) recently described an antigen detection assay (inh-ELISA) for P. brasiliensis gp43 and gp70 molecules with good potential for diagnosis and follow-up of patients with PCM.
PCM is acquired either by inhalation of mycelial propagules of the fungus in nature or by reactivation of latent foci of infection. Pulmonary involvement is characteristic of PCM, and BAL fluid would accordingly be expected to contain anti-gens. In other pulmonary diseases, such as histoplasmosis, Wheat et al. (24) found elevated levels ofHistoplasmaantigens in BAL fluid in 19 (70.3%) of 27 cases. Graybill et al. (13) also reported the presence ofHistoplasmaantigens in BAL fluid of mice with experimentally induced histoplasmosis.
In the present study, P. brasiliensis gp43 and gp70 were detected in all BAL fluid samples from patients with pulmo-nary PCM, with mean antigen concentrations of 9.38 g/ml and 4.37g/ml, respectively. Our results suggest that monitor-ing specific antigens ofP. brasiliensisin BAL samples may be
helpful in determining a diagnosis of pulmonary PCM, partic-ularly when the infection is in its initial stage. Since antigen values for gp43 were always higher than those found for gp70, assaying only for gp43 may prove sufficient for that purpose. No antibodies were detected in BAL fluids when tested by ID, whereas antibodies against both antigens were detected by ELISA, although the titers were low. However, when sera from these patients were tested by ID, 85.18% of them reacted positively, with titers ranging from 1:8 to 1:64. Despite the limited number of patients in this study, the data suggest that antigen detection in BAL by inh-ELISA or the detection of specific antibodies by ELISA may be equally sensitive in iden-tifying pulmonary PCM. The fact that gp43 and gp70 antigens were detected in the sera of 100% of these patients indicates that this test, as well as the detection of antigens in BAL fluid, has a role to play in the diagnosis of patients with suspected pulmonary PCM, diffuse pulmonary infiltrates, or unexplained febrile illnesses. However, antibody detection by ELISA as a routine procedure is less cumbersome and time-consuming than antigen detection. Hence, testing of BAL samples for antigens would be recommended only when a suspected pa-tient has either negative or inconsistent results for antibody
detection or negative results in the direct examination of spu-tum or when sera of suspected patients are negative by ID.
Our results show that P. brasiliensis antigen detection in BAL fluid is a valuable tool for diagnosis of pulmonary PCM. Nevertheless, the limited clinical and radiological information available for the small number of patients enrolled in our study proscribed the possibility of establishing a correlation between antigen levels and the severity of the disease.
This work was supported by the Fundac¸a˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo.
REFERENCES
1.Blotta, M. H. S. L., R. L. Mamoni, S. J. Oliveira, A. S. Noue´r, P. M. O. Papaiordanou, A. Gouveia, and Z. P. de Camargo.1999. Endemic regions of paracoccidioidomycosis in Brazil: a clinical and epidemiologic study of 584 cases in southeast region. Am. J. Trop. Med. Hyg.61:390–394.
2.Bradford, M.1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye bind-ing. Anal. Biochem.72:248–254.
3.Brummer, E., E. Castan˜eda, and A. Restrepo.1993. Paracoccidioidomycosis: an update. Clin. Microbiol. Rev.2:89–117.
4.de Camargo, Z. P., C. Unterkircher, S. P. Campoy, and L. R. Travassos.
1988. Production ofParacoccidioides brasiliensisexoantigens for immunodif-fusion tests. J. Clin. Microbiol.26:2147–2151.
5.de Camargo, Z. P., R. Berzaghi, C. C. Amaral, and S. H. Marques-da-Silva.
TABLE 1. Serological results for 27 patients with pulmonary PCM and control groups evaluated by inh-ELISA, immunodiffusion, and ELISA
Subject no.
BAL fluid antigen concn
(g/ml)a BAL fluid ELISA result(dilution)b Serum antigen concn(g/ml)a ID antibody titer in:
gp43 gp70 anti-gp43 anti-gp70 gp43 gp70 BAL fluid Serum
1 11.25 5.27 ⫹(1:200) ⫹(1:100) 15.0 6.38 0 1:16
2 12.75 4.16 ⫹(1:400) ⫹(1:50) 15.0 9.12 0 1:32
3 3.0 0.93 ⫹(1:200) ⫹(1:50) 21.0 11.21 0 1:16
4 16.5 5.64 ⫹(1:50) ⫹(1:50) 19.5 7.5 0 1:8
5 4.16 2.67 ⫹(1:200) ⫹(1:100) 13.5 7.12 0 0
6 6.38 3.39 ⫹(1:200) ⫹(1:50) 14.25 30.0 0 1:16
7 9.0 4.53 ⫹(1:50) ⫹(1:50) 27.0 10.2 0 1:32
8 19.5 4.90 ⫹(1:50) ⫹(1:50) 16.5 13.87 0 1:64
9 6.75 4.22 ⫹(1:50) ⫹(1:50) 14.25 1.87 0 1:2
10 22.5 12.75 ⫹(1:200) ⫹(1:50) 15.0 8.83 0 1:8
11 9.65 5.02 ⫹(1:200) ⫹(1:50) 18.0 4.53 0 1:4
12 8.71 4.87 ⫹(1:50) ⫹(1:50) 7.12 2.85 0 1:16
13 5.92 3.01 ⫹(1:50) ⫹(1:50) 3.29 2.76 0 1:8
14 15.05 7.15 ⫹(1:200) ⫹(1:50) 17.57 5.27 0 1:16
15 16.0 4.89 ⫹(1:400) ⫹(1:100) 9.45 4.64 0 1:64
16 11.75 6.0 ⫹(1:400) ⫹(1:50) 12.76 7.23 0 1:64
17 8.06 3.79 ⫹(1:200) ⫹(1:100) 10.67 6.63 0 0
18 3.25 1.20 ⫹(1:100) ⫹(1:50) 12.66 8.68 0 1:16
19 9.65 4.17 ⫹(1:200) ⫹(1:100) 19.34 6.69 0 1:16
20 11.87 7.79 ⫹(1:400) ⫹(1:100) 29.76 11.12 0 0
21 10.21 5.71 ⫹(1:50) ⫹(1:50) 13.46 6.93 0 1:16
22 2.71 1.00 ⫹(1:50) ⫹(1:50) 9.55 3.86 0 1:32
23 3.09 2.01 ⫹(1:50) ⫹(1:50) 13.89 7.78 0 1:64
24 6.58 3.79 ⫹(1:200) ⫹(1:100) 19.33 7.44 0 1:8
25 7.21 4.29 ⫹(1:200) ⫹(1:50) 22.37 7.93 0 1:16
26 8.87 3.0 ⫹(1:100) ⫹(1:50) 10.52 3.03 0 1:8
27 3.0 1.89 ⫹(1:100) ⫹(1:50) 18.65 8.98 0 0
Mean 9.38 4.37 15.53 7.86
Control Ac
⬍0.23 ⬍0.21 0 0
Control Bd
⬍0.23 ⬍0.21 0 0
aAntigen detection by inh-ELISA. bAntibody detection by ELISA.
⫹, positive. 0, negative.
cTen BAL fluid samples from patients with noninfectious diseases were negative for antigens and antibodies (control patients). dTen BAL fluid samples from patients with other infectious diseases were negative for antigens and antibodies (control patients).
2003. Simplified method for producingParacoccidioides brasiliensis exoanti-gens for use in immunodiffusion tests. Med. Mycol.41:539–542.
6.Del Negro, G., C. S. Lacaz, V. A. Zamith, and A. M. Siqueira.1994. General clinical aspects: polar forms of paracoccidioidomycosis, the disease in child-hood, p. 225–232.InM. Franco, C. S. Lacaz, A. Restrepo-Moreno, and G. Del Negro (ed.), Paracoccidioidomycosis. CRC Press, Boca Raton, Fla. 7.Dupont, B., M. Huber, S. J. Kim, and J. E. Bennet.1987. Galactomannan
antigenemia and antigenuria in aspergillosis studies in patients and experi-mental infected rabbits. J. Infect. Dis.155:1–11.
8.Ferreira, R. P., B. Yu, Y. Niki, and D. Armstrong. 1990. Detection of Candidaantigenuria in disseminated candidiasis by immunoblotting. J. Clin. Microbiol.28:1075–1078.
9.Franco, M., M. R. Montenegro, R. P. Mendes, S. A. Marques, N. L. Dillon, and N. G. S. Mota.1987. Paracoccidioidomycosis: a recently proposed clas-sification on its clinical forms. Rev. Soc. Bras. Med. Trop.20:129–132. 10.Franco, M., M. T. S. Perac¸oli, A. M. V. C. Soares, M. R. Montenegro, R. P.
Mendes, and D. A. Meira.1993. Host-parasite relationships in paracoccid-ioidomycosis. Curr. Trop. Med. Mycol.5:115–149.
11.Go´mez, B. L., J. I. Figueroa, A. J. Hamilton, B. Ortiz, M. A. Robledo, R. J. Hay, and A. Restrepo.1997. Use of monoclonal antibodies in diagnosis of paracoccidioidomycosis: new strategies for detection of circulating antigens. J. Clin. Microbiol.35:3278–3283.
12.Go´mez. B. L., J. I. Figueroa, A. J. Hamilton, B. I. Ortiz, M. A. Tobo´n, R. J. Hay, and A. Restrepo.1998. Antigenemia in patients with paracoccidioid-omycosis: detection of the 87-kilodalton determinant during and after anti-fungal therapy. J. Clin. Microbiol.36:3309–3316.
13.Graybill, J. R., E. Palou, and J. Ahrens. 1986. Treatment of murine histoplasmosis with UK 49,858 (fluconazole). Am. Rev. Respir. Dis.134:
768–770.
14.Haynes, K. A., J. P. Latge´, and T. R. Rogers.1990. Detection ofAspergillus antigens associated with invasive infection. J. Clin. Microbiol.28:2040–2044. 15.Marques-da-Silva, S. H., A. L. Colombo, M. H. S. L. Blotta, J. D. Lopes, F. Queiroz-Telles, and Z. P. de Camargo.2003. Detection of circulating gp43 antigen in serum, cerebrospinal fluid, and bronchoalveolar lavage fluid of patients with paracoccidioidomycosis. J. Clin. Microbiol.41:3675–3680.
16.Marques-da-Silva, S. H., F. Queiroz-Telles, A. L. Colombo, M. H. S. L. Blotta, J. D. Lopes, and Z. P. de Camargo.2004. Monitoring gp43 antigen-emia in paracoccidioidomycosis patients during therapy. J. Clin. Microbiol.
42:2419–2424.
17.Marques-da-Silva, S. H., D. Mattos Grosso, J. D. Lopes, A. L. Colombo, M. H. S. L. Blotta, F. Queiroz-Telles, and Z. P. de Camargo.2004. Detection of Paracoccidioides brasiliensisgp70 circulating antigen and follow-up of patients undergoing antimycotic therapy. J. Clin. Microbiol.42:4480–4486. 18.Marques-da-Silva, S. H., A. L. Colombo, M. H. S. L. Blotta, F.
Queiroz-Telles, J. D. Lopes, and Z. P. de Camargo.2005. Diagnosis of neuropara-coccidioidomycosis by detection of circulating antigen and antibody in cere-brospinal fluid. J. Clin. Microbiol.43:4680–4683.
19.Matthews, R. C.1996. Comparative assessment of the detection of candidal antigens as a diagnostic tool. J. Med. Vet. Mycol.34:1–10.
20.Mattos Grosso, D., S. R. Almeida, M. Mariano, and J. D. Lopes.2003. Characterization of gp70 and anti-gp70 monoclonal antibodies in Paracoc-cidioides brasiliensispathogenesis. Infect. Immun.71:6534–6542.
21.Puccia, R., S. Schenkman, P. A. Gorin, and L. R. Travassos.1986. Exocel-lular components ofParacoccidioides brasiliensis: identification of a specific antigen. Infect. Immun.53:199–206.
22.Ratto, O. R., and J. E. Afonso.1994. Pulmonary lesions: clinical and func-tional aspects, p. 271–279.InM. Franco, C. S. Lacaz, A. Restrepo-Moreno, and G. Del Negro (ed.), Paracoccidioidomycosis. CRC Press, Boca Raton, Fla.
23.Tobo´n, A. N., C. A. Agudelo, M. L. Osorio, D. L. Alvarez, M. Arango, L. E. Cano, and A. Restrepo.2003. Residual pulmonary abnormalities in adult patients with chronic paracoccidioidomycosis: prolonged follow-up after itra-conazole therapy. Clin. Infect. Dis.37:898–904.
24.Wheat, L. J., P. Connoly-Stringfield, B. Williams, K. Connoly, R. Blair, M. Bartlett, and M. Durkin.1992. Diagnosis of histoplasmosis in patients with the acquired immunodeficiency syndrome by detection ofHistoplasma capsulatumpolysaccharide antigen in bronchoalveolar lavage fluid. Am. Rev. Resp. Dis.145:1421–1424.
